Ocuphire Pharma, Inc. (OCUP)
| Market Cap | 57.17M |
| Revenue (ttm) | -1.15M |
| Net Income (ttm) | -63.05M |
| Shares Out | 10.92M |
| EPS (ttm) | -8.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $4.55 |
| Previous Close | $4.43 |
| Change ($) | 0.12 |
| Change (%) | 2.71% |
| Day's Open | 4.59 |
| Day's Range | 4.22 - 4.59 |
| Day's Volume | 641,397 |
| 52-Week Range | 1.70 - 13.81 |
Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication
Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization
Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy ...
APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy
FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of...
Ocuphire Pharma Inc (NASDAQ: OCUP) stock is soaring in the premarket in reaction to positive data from MIRA-2 Phase 3 trial evaluating Nyxol. Nyxol is an eye drop formulation of phentolamine mesylate de...
Nyxol Meets Its Primary and Multiple Secondary Endpoints Including Statistically Significant Efficacy Returning Subjects More Rapidly to Normal Pupil Size Across a Breadth of Dilating Agents and Iris Co...
FARMINGTON HILLS, Mich., March 10, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapie...
Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design
HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th Oppenheimer Healthcare Conference at 9:20 am ET on March 18th
Nyxol and Low-Dose (0.4%) Pilocarpine Combination to Target Improvement in Near Vision in a Presbyopic Population
FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies...
Durability of Nyxol's Pupil Constricting Effects Using an Evening Dosing Regimen Informs Dosing Strategy for Phase 2 Trial in Presbyopia and Phase 3 Trial in NVD
FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatm...
ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected t...
ROCKVILLE, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that at its special meeting of stockholders held on November 2, 2020, Rexahn's sto...
NEW YORK, June 29, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) and Ocuphire Pharma, ...
New York, New York--(Newsfile Corp. - June 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rexahn Pharmaceuticals, Inc. (NASDAQ: RE...
Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates
About OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to tar... [Read more...]
| Industry Biotechnology | |
| CEO Douglas Swirsky | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol OCUP |